全球三分之二的癌症发生在低/中等收入国家 (LMIC)。中美洲北部是西半球最大的中低收入国家地区，缺乏指导癌症控制的癌症登记处。我们在洪都拉斯西部农村地区进行了一项胃癌 (GC) 生存研究，洪都拉斯是拉丁美洲胃癌发病率最高的地区之一。我们对 2002 年至 2015 年期间诊断出的胃癌事件队列进行了积极的随访和家访研究。地区胃癌登记处主要用于病例识别，并对医院数据和国家死亡证明进行完整性检查。使用Cox回归模型进行生存计算。741/774名患者（95.7%）实现了生存随访。 74.1%（n=549）进行了入户访谈。 65.7%为男性，诊断时中位年龄为64岁，24.5%<55岁。 43.9%的肿瘤有幽门梗阻。 45.2%、43.2% 和 7.3% 的组织学类型分别为肠型、弥漫型和混合型。 24.7%的患者接受了治疗。男性和女性的 5 年生存率为 9.9%，年龄 <45 岁的患者为 7.7%，弥漫性 GC 为 7.9%。中位生存时间为 4.8 个月 (95% CI,4.2-5.6)。在最终的包含年龄、性别、劳伦亚型和贫困指数的 Cox 回归模型中，只有治疗与生存显着相关（HR 2.43，95%CI，1.8-3.2）。中美洲乡村。大多数患者患有晚期疾病，少数患者可以获得治疗。研究结果对中美洲中低收入国家和美国拉丁裔人群的癌症控制具有重要意义。

Two-thirds of global cancer occur in low/middle income countries (LMICs). Northern Central America is the largest LMIC region in the western hemisphere, and lack cancer registries to guide cancer control. We conducted a gastric cancer (GC) survival study in rural western Honduras, characterized as having among the highest GC incidence rates in Latin America.The cohort of incident GC diagnosed between 2002-2015 was studied with active follow-up, with household visits. The regional gastric cancer registry was primary for case identification, with completeness examination with hospital data and national death certificates. Cox regression models were used for survival calculations.Survival follow-up was achieved in 741/774 patients (95.7%). Household interviews were conducted in 74.1% (n=549). 65.7% were male, median age at diagnosis was 64 years, 24.5% were <55. 43.9% of tumors had pyloric obstruction. 45.2%, 43.2%, and 7.3% of histology was intestinal, diffuse, and mixed, respectively. 24.7% patients received treatment. 5-year survival rates were 9.9% for both males and females, 7.7% for age <45, and 7.9% for diffuse GC. Median survival time was 4.8 months (95%CI,4.2-5.6). In the final Cox regression model including age, sex, Lauren subtype, and poverty index, only treatment was significantly associated with survival (HR 2.43, 95%CI,1.8-3.2).Markedly low gastric cancer 5-year survival rates are observed in rural Central America. The majority of patients present with advanced disease, and a minority have access to therapy.The findings have implications for cancer control in the Central America LMICs and for U.S. Latino populations.